



## PRESS RELEASE

### Active Biotech to Present at the 33rd Annual J.P. Morgan Healthcare Conference

**Lund, Sweden, January 12, 2015** - Active Biotech (NASDAQ STOCKHOLM: ACTI) is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference held January 12-15, 2015 in San Francisco, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include the Phase III projects with **laquinimod**, a novel oral immunomodulatory drug primarily for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical, and **tasquinimod**, developed in collaboration with Ipsen, primarily for the treatment of prostate cancer. Also, the pre-clinical **ISI** project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to – [www.activebiotech.com](http://www.activebiotech.com).

The presentation will take place on **January 15**, at **10:00 a.m. local PST / 7:00 p.m. Central European Time**.

#### **For further information, please contact:**

Hans Kolam, CFO

Phone: +46 (0)46 19 20 44

E-mail: [hans.kolam@activebiotech.com](mailto:hans.kolam@activebiotech.com)

***Active Biotech AB (publ)** (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.*

Active Biotech AB (Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 46 19 20 00

Fax: +46 46 19 11 00

*Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8.30 am CET on January 12, 2015.*